Oral delivery of nucleic acid drugs

Oral Delivery of Macromolecular Drugs

Volumn , Issue , 2009, Pages 223-236

  Martien, Ronny ^a  

^a GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900774648     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0200-9_12     Document Type: Chapter

References (57)

1. Agrawal, S., X. Zhang, Z. Lu, H. Zhao, J. M. Tamburin, J. Yan, H. Cai, R. B. Diasio, I. Habus and Z. Jiang (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 50(4):571-6.
2. Audouy, S., G. Molema, L. de Leij and D. Hoekstra (2000). Serum as a modulator of lipoplexmediated gene transfection: dependence of amphiphile, cell type and complex stability. J Gene Med 2(6):465-76.
3. Bernkop-Schnurch, A., C. E. Kast and D. Guggi (2003). Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J Control Release 93(2):95-103.
4. Bernkop-Schnurch, A., A. H. Krauland, V. M. Leitner and T. Palmberger (2004). Thiomers: potential excipients for non-invasive peptide delivery systems. Eur J Pharm Biopharm 58(2):253-263.
5. Bernkop-Schnurch, A., H. Zarti and G. F. Walker (2001). Thiolation of polycarbophil enhances its inhibition of intestinal brush border membrane bound aminopeptidase N. J Pharma Sci 90(11):1907-1914.
6. Borges, O., G. Borchard, J. C. Verhoef, A. de Sousa and H. E. Junginger (2005). Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 299(1-2):155-166.
7. Crooke, S. T. (1998). An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 8(2):115-22.
8. El Ouahabi, A., M. Thiry, V. Pector, R. Fuks, J. M. Ruysschaert and M. Vandenbranden (1997). The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett 414(2):187-92.
9. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber and T. Tuschl (2001). Duplexes of 21-nucleotide RNAs mediate RNA inerference in cultured mammalian cells. Nature 411:494-498.
10. Ellington, A. D. and J. Szostak (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822.
11. Ess, K. C., J. J. Hutton and B. J. Aronow (1994). Double-stranded phosphorothioate oligonucleotide modulation of gene expression. Ann New York Acad Sci 716:321-332.
12. Fasano, A. (1998). Novel approaches for oral delivery of macromolecules. J Pharm Sci 87(11):1351-6.
13. Fire, A., S. Q. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver and C. C. Mello (1998). Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
14. Fraunhofer, W., G. Winter and C. Coester (2004). Asymmetrical flow field-flow fractionation and multiangle light scattering for analysis of gelatin nanoparticle drug carrier systems. Anal Chem 76(7):1909-20.
15. Gardlik, R., R. Palffy, J. Hodosy, J. Lukacs, J. Turna and P. Celec (2005). Vectors and delivery systems in gene therapy. Med Sci Monit 11(4):RA110-21.
16. Guerrier, T. C., K. Gardiner, T. Marsh, N. Pace and S. Altman (1983). The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 35:849-857.
17. Guggi, D., N. Langoth, M. H. Hoffer, M. Wirth and A. Bernkop-Schnurch (2004). Comparative evaluation of cytotoxicity of a glucosamine-TBA conjugate and a chitosan-TBA conjugate. Int J Pharm 278(2):353-360.
18. Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J. L. Villeval, C. C. Fraser, M. Cavazzana-Calvo and A. Fischer (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348(3):255-6.
19. Ishizawa, T., M. Hayashi and S. Awazu (1987). Enhancement of jejunal and colonic absorption of fosfomycin by promoters in the rat. J Pharm Pharmacol 39:892-895.
20. Johnston, S. A., A. M. Talaat and M. J. McGuire (2002). Genetic immunization: what's in a name? Arch Med Res 33(4):325-9.
21. Kai, E. and T. Ochiya (2004). A method for oral DNA delivery with N-acetylated chitosan. Pharmaceutical Res 21(5):838-843.
22. Kataoka, K. (1998). [Intracellular gene delivery by polymer micelle vectors]. Nippon Rinsho 56(3):718-23.
23. Katayose, S. and K. Kataoka (1997). Water-soluble polyion complex associates of DNA and poly (ethylene glycol)-poly (L-lysine) block copolymer. Bioconjug Chem 8(5):702-7.
24. Kurreck, J., E. Wyszko, C. Gillen and V. A. Erdmann (2002). Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 30(9):1911-8.
25. Lampela, P., J. Raisanen, P. T. Mannisto, S. Yla-Herttuala and A. Raasmaja (2002). The use of low-molecular-weight PEIs as gene carriers in the monkey fibroblastoma and rabbit smooth muscle cell cultures. J Gene Med 4:205-214.
26. Lindmark, T., J. Soderholm, G. Olaison, G. Alvan, G. Ocklind and P. Artursson (1997). Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm Res 14:930-935.
27. Loretz, B., F. Foger, M. Werle and A. Bernkop-Schnurch (2006). Oral gene delivery: Strategies to improve stability of pDNA towards intestinal digestion. J Drug Target 14(5):311-9.
28. Lundstrom, K. and T. Boulikas (2003). Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2:471-86.
29. Ma, H. and S. L. Diamond (2001). Nonviral gene therapy and its delivery systems. Curr Pharm Biotechnol 2(1):1-17.
30. Ma, T., D. Hollander, D. Bhalla, H. Nguyen and P. Krugliak (1992). IEC-18, a nontransformed small intestinal cell line for studying epithelial permeability. J Lab Clin Med 120:329-341.
31. Mansouri, S., Y. Cuie, F. Winnik, Q. Shi, P. Lavigne, M. Benderdour, E. Beaumont and J. C. Fernandes (2006). Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 27(9):2060-2065.
32. Martien, R., B. Loretz, A. M. Sandbichler and Bernkop Schnürch A (2008). Thiolated chitosan nanoparticles: transfection study in the Caco-2 differentiated cell culture. Nanotechnology 19:045101 (9 pp).
33. Martien, R., B. Loretz, M. Thaler, S. Majzoob and A. Bernkop-Schnurch (2007). Chitosanthioglycolic acid conjugate: an alternative carrier for oral nonviral gene delivery? J Biomed Mater Res A 82(1):1-9.
34. Mastrobattista, E., W. E. Hennink and R. M. Schiffelers (2007). Delivery of nucleic acids. Pharm Res 24(8):1561-3.
35. Mastrobattista, E., M. A. van der Aa, W. E. Hennink and D. J. Crommelin (2006). Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 5(2):115-21.
36. Merdan, T., J. Kopecek and T. Kissel (2002). Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54(5):715-58.
37. Mestecky, J. (1987). The common mucosal immune-system and current strategies for induction of immune-responses in external secretions. J Clin Immunol 7(4):265-276.
38. Newman, C. M., A. Lawrie, A. F. Brisken and D. C. Cumberland (2001). Ultrasound gene therapy: on the road from concept to reality. Echocardiography 18(4):339-47.
39. Patil, S. D., D. G. Rhodes and D. J. Burgess (2005). DNA-based therapeutics and DNA delivery systems: a comprehensive review. Aaps J 7(1):E61-77.
40. Raoof, A. A., P. Chiu, Z. Ramtoola, I. K. Cumming, C. Teng, S. P. Weinbach, G. E. Hardee, A. A. Levin and R. S. Geary (2004). Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci 93(6):1431-9.
41. Raoof, A. A., Z. Ramtoola, B. McKenna, R. Z. Yu, G. Hardee and R. S. Geary (2002). Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci 17(3):131-8.
42. Raper, S. E., N. Chirmule, F. S. Lee, N. A. Wivel, A. Bagg, G. P. Gao, J. M. Wilson and M. L. Batshaw (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80(1-2):148-58.
43. Riordan, M. L and J. C. Martin (1991). Oligonucleotide based therapeutics. Nature 350:442-443.
44. Rubanyi, G. M. (2001). The future of human gene therapy. Mol Aspects Med 22(3):113-42.
45. Sandberg, J. W., C. Lau, M. Jacomino, M. Finegold and S. J. Henning (1994). Improving access to intestinal stem-cells as a step toward intestinal gene-transfer. Human Gene Therapy 5(3):323-329.
46. Santiago, F. S. and L. M. Khachigian (2001). Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J Mol Med 79(12):695-706.
47. Schaffer, D. V., N. A. Fidelman, N. Dan and D. A. Lauffenburger (2000). Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol Bioeng 67(5):598-606.
48. Stein, C. A. (2001). The experimental use of antisense oligonucleotide: a guide for the perplexed. J Clin Invest 108:641-644.
49. Stull, R. A. and F. C. Szoka, Jr. (1995). Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res 12(4):465-83.
50. Sweetser, D. A., S. M. Hauft, P. C. Hoppe, E. H. Birkenmeier and J. I. Gordon (1988). Transgenic mice containing intestinal fatty acid-binding protein human growth-hormone fusion genes exhibit correct regional and cell-specific expression of the reporter gene in their small-intestine. Proc Natl Acad Sci USA 85(24):9611-9615.
51. Thomas, M., Q. Ge, J. J. Lu, J. Chen and A. M. Klibanov (2005). Crosslinked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm. Res 22:373-380.
52. Tomlinson, E. and A. P. Rolland (1996). Controllable gene therapy - pharmaceutics of nonviral gene delivery systems. J Controlled Release 39(2-3):357-372.
53. Tsutsumi, K., S. Li, A. Ghanem, N. Ho and H. WI. (2003). A systematic examination of the in vitro using chamber and the in situ single-pass perfusion model systems in rat ileum permeation of model solutes. J Pharm Sci 92:344-359.
54. Uherek, C. and W. Wels (2000). DNA-carrier proteins for targeted gene delivery. Adv Drug Deliv Rev 44(2-3):153-66.
55. van der Aa, M. A., E. Mastrobattista, R. S. Oosting, W. E. Hennink, G. A. Koning and D. J. Crommelin (2006). The nuclear pore complex: the gateway to successful nonviral gene delivery. Pharm Res 23(3):447-59.
56. Yu, J. Y., S. L. DeRuiter and D. L. Turnner (2002). RNA interference by expression of short interferencing and hair pin RNAs in mammalian cells. Proc Natl Acad Sci 99:6047-6052.
57. Zamecnik, P. C. and M. L. Stephenson (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci 75:280-284.